Scientific literature confirms that AZT and related nucleoside analogues selectively inhibit HIV reverse transcriptase to suppress viral replication while minimizing impact on normal cellular functions.
The claim that AZT selectively targets HIV reverse transcriptase is a foundational principle of antiretroviral therapy supported by numerous studies detailing the specific inhibition of viral reverse transcriptase over human cellular machinery. The provided papers corroborate the targeted mechanism of nucleoside-analog reverse transcriptase inhibitors.